News|Articles|June 8, 2026

Vaccine Trials at an Inflection Point: Operational, Regulatory, and Public Trust Challenges

From rising costs and regulatory uncertainty to persistent vaccine hesitancy, sponsors face mounting pressure to standardize operations, build community trust, and develop the behavioral capabilities needed to run vaccine trials effectively in a rapidly shifting environment.

The vaccine development landscape is under pressure from multiple directions simultaneously. Sponsors that build flexible, standardized, and community-informed trial programs will be better positioned to absorb regulatory change, accelerate timelines, and earn the public trust that ultimately determines whether vaccines reach the populations who need them.

Related to this article

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.